Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of depemokimab versus mepolizumab or benralizumab in severe eosinophilic asthma
MOH_2023-03-26_012475Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Depemokimab + placebo with Mepolizumab or benralizumab + placebo (2 arms). Primary endpoint: Asthma worsening rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
depemokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on MOH_2023-03-26_012475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-26_012475.